atHeart Medical celebrates one of its veteran engineers who has been working on the reSept ASD Occluder since the very early days.
The development of the reSept ASD Occluder started over 15 years ago with a small team of dedicated medical device engineers. Over time, the team significantly expanded with many more talents and competencies to turn a concept into reality. Today, over 100 patients have been implanted with reSept, with the earliest implanted patients being more than 10 years ago.
“We are proud to celebrate such a significant milestone in our journey – 15 years of team dedication and progress on our reSept ASD Occluder”, said Laurent Grandidier, atHeart Medical CEO. “Bringing such innovation to patients requires time, talent and grit. This celebration is a fantastic testimony to atHeart’s unwavering commitment to bringing a novel solution to congenital heart defect patients globally.
The ASCENT ASD study is currently enrolling patients in the USA, France, Switzerland and Canada. For more information about ASCENT ASD and the implanting centers please click here.
Unlike existing ASD occluders, the reSept ASD Occluder has a metal-free frame. Its structure consists of two fabric disks connected by naturally resorbable synthetic filaments. The filaments hold the disks closely together until tissue covers and firmly embeds the disks in the new, repaired septum. When no longer needed, the filaments dissolve in the body. They turn into water and CO2 to be naturally expelled and exhaled within two years.
Please follow the links for further information on ASDs and on the reSept ASD Occluder.